Cerebrospinal fluid level of phosphorylated neurofilament heavy chain is higher in converting clinically isolated syndrome and correlates with CAMP response element-binding protein concentration

被引:0
作者
Gencer, Mehmet [1 ]
Koral, Gizem [2 ]
Sanli, Elif [2 ]
Cirak, Selen [2 ]
Akbayir, Ece [2 ]
Yuceer, Hande [2 ]
Kizilay, Tugce [1 ]
Yildiz, Ruziye Erol [1 ]
Yentur, Sibel Penbe [3 ]
Yilmaz, Vuslat [2 ]
Tuzun, Erdem [2 ]
Turkoglu, Recai [1 ]
机构
[1] Istanbul Haydarpasa Numune Training & Res Hosp, Dept Neurol, Istanbul, Turkey
[2] Istanbul Univ, Aziz Sancar Inst Expt Med, Dept Neurosci, Istanbul, Turkey
[3] Istanbul Univ, Istanbul Fac Med, Dept Physiol, Istanbul, Turkey
来源
NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY | 2021年 / 38卷 / 04期
关键词
Biomarker; cAMP response element-binding protein; clinically isolated syndrome; multiple sclerosis; neurofilament; MULTIPLE-SCLEROSIS; NEURITE OUTGROWTH; DISEASE; ACTIVATION; PATHWAY; LIGHT; MODEL;
D O I
10.4103/nsn.nsn_144_21
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: Prevision of conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) is required to avoid unnecessary use of immunomodulating agents and to recognize patients with high disease activity. Our aim was to evaluate the value of phosphorylated neurofilament heavy chain (pNFH, a marker for neuroaxonal degeneration) and Cyclic adenosine monophosphate response element-binding protein (cAMP response element-binding protein [CREB], a marker for neuroregeneration) levels in the prediction of conversion from CIS to MS. Methods: Twenty-three consecutively recruited treatment-naive CIS patients were followed for 36 months. pNFH and CREB levels were measured in the first episode cerebrospinal fluid (CSF) and the serum of 12 converting (CIS-MS) and 11 nonconverting CIS patients (CIS-CIS) by enzyme-linked immunosorbent assay. Results: Baseline CSF but not serum samples of CIS-CIS patients displayed significantly lower pNFH levels compared to patients with CIS-MS. The analysis of receiver operating characteristic curve presented a high specificity for the prediction of MS conversion for the CSF pNFH cut-off level of 730.9 pg/ml. CSF pNFH levels significantly correlated with serum and CSF CREB levels. Higher baseline CSF pNFH and CREB levels were associated with more rapid progression to MS or increased disability scores. Conclusion: CSF pNFH measurement may potentially determine MS patients with unfavorable clinical progression after the first attack. pNFH and CREB appear to be increased in parallel in CSF of CIS patients with higher disease activity. These results suggest that neurofilaments are not only indicators of axonal degeneration but also partly a marker of neuronal differentiation and new axon regeneration mediated by CREB signaling pathway.
引用
收藏
页码:256 / 261
页数:6
相关论文
共 25 条
  • [1] Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex
    Alghamdi, Badrah Saeed
    AboTaleb, Hanin Abdulbaset
    [J]. JOURNAL OF INTEGRATIVE NEUROSCIENCE, 2020, 19 (02) : 229 - 237
  • [2] The potential of serum neurofilament as biomarker for multiple sclerosis
    Bittner, Stefan
    Oh, Jiwon
    Havrdova, Eva Kubala
    Tintore, Mar
    Zipp, Frauke
    [J]. BRAIN, 2021, 144 : 2954 - 2963
  • [3] MRI features associated with rapid disease activity in clinically isolated syndrome patients at high risk for multiple sclerosis
    De Lury, Amy
    Bisulca, Joseph
    Coyle, Patricia K.
    Peyster, Robert
    Bangiyev, Lev
    Duong, Tim Q.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [4] The Evolution of Neurofilament Light Chain in Multiple Sclerosis
    Ferreira-Atuesta, Carolina
    Reyes, Saul
    Giovanonni, Gavin
    Gnanapavan, Sharmilee
    [J]. FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [5] Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis
    Gencer, Mehmet
    Akbayir, Ece
    Sen, Melis
    Arsoy, Erdil
    Yilmaz, Vuslat
    Bulut, Nesrin
    Tuzun, Erdem
    Turkoglu, Recai
    [J]. NEUROLOGICAL SCIENCES, 2019, 40 (05) : 1067 - 1070
  • [6] Neurofilaments in disease: what do we know?
    Gordon, Brian A.
    [J]. CURRENT OPINION IN NEUROBIOLOGY, 2020, 61 : 105 - 115
  • [7] Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
    Gresle, M. M.
    Liu, Y.
    Dagley, L. F.
    Haartsen, J.
    Pearson, F.
    Purcell, A. W.
    Laverick, L.
    Petzold, A.
    Lucas, R. M.
    Van der Walt, A.
    Prime, H.
    Morris, D. R.
    Taylor, B. V.
    Shaw, G.
    Butzkueven, H.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11) : 1209 - 1213
  • [8] Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis
    Hakansson, I.
    Tisell, A.
    Cassel, P.
    Blennow, K.
    Zetterberg, H.
    Lundberg, P.
    Dahle, C.
    Vrethem, M.
    Ernerudh, J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (05) : 703 - 712
  • [9] Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood
    Hendricks, Robert
    Baker, Dana
    Brumm, Jochen
    Davancaze, Teresa
    Harp, Chris
    Herman, Ann
    von Budingen, H-Christian
    Townsend, Michael
    Fischer, Saloumeh K.
    [J]. BIOANALYSIS, 2019, 11 (15) : 1405 - 1418
  • [10] The CREB/CRTC2 pathway modulates autoimmune disease by promoting Th17 differentiation
    Hernandez, Jeniffer B.
    Chang, Christina
    LeBlanc, Mathias
    Grimm, David
    Le Lay, John
    Kaestner, Klaus H.
    Zheng, Ye
    Montminy, Marc
    [J]. NATURE COMMUNICATIONS, 2015, 6